Use of trastuzumab emtansine (T-DM1; K) after pertuzumab plus trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

被引：0
|
作者：
Sanglier, T. [1 ]
Fabi, A. [2 ]
Flores, C. [3 ]
Flahavan, E. [4 ]
Lindegger, N. [5 ]
Montemurro, F. [6 ]
机构：
[1] F Hoffmann La Roche Ltd, RWD Oncol, Basel, Switzerland
[2] Ist Nazl Tumori Regina Elena, Oncol Med, Rome, Italy
[3] Genentech Inc, RWD Oncol, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, RWD Oncol, Welwyn Garden City, Herts, England
[5] F Hoffmann La Roche Ltd, Med Affairs Oncol, Global Prod Dev, Basel, Switzerland
[6] Candiolo Canc Inst, Day Hosp Oncol Multidisciplinare, Candiolo, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
    Quang Anh Le
    Bae, Yuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Treatment with tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A real-world study
    Yin, Yongmei
    Li, Wei
    Huang, Xiang
    Sun, Chunxiao
    Hua, Yijia
    Jin, Nan
    Wu, Xinyu
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
    Dan Lu
    Chunze Li
    Matthew Riggs
    Daniel Polhamus
    Jonathan French
    Priya Agarwal
    Shang-Chiung Chen
    Shweta Vadhavkar
    Monika Patre
    Alexander Strasak
    Angelica Quartino
    Jin Yan Jin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 175 - 185
  • [24] Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study
    Yardley, Denise Aysel
    Krop, Ian E.
    LoRusso, Patricia
    Robert, Nicholas J.
    Mayer, Musa
    Abidoye, Oyewale O.
    Lai, Catherine
    Yoo, Bongin
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [25] Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study
    Martinez-Garcia, J.
    Puertes Boix, A.
    Sanchez Henarejos, P.
    Jimenez Lucas, M. D.
    Sanchez Saura, A.
    Luengo, M.
    Carrillo Vicente, R.
    Martinez Ortiz, M. J.
    Balsalobre, J.
    de la Morena Barrio, P. D. L. M.
    Garcia Garre, E.
    Garcia, E.
    Marin, G.
    Garcia Torralba, E.
    Ayala de la Pena, F.
    Collado, D.
    Lopez, A.
    Quiros, T.
    Sanchez, D. A.
    Romero, J. L. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S358 - S358
  • [26] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
    Lu, Dan
    Li, Chunze
    Riggs, Matthew
    Polhamus, Daniel
    French, Jonathan
    Agarwal, Priya
    Chen, Shang-Chiung
    Vadhavkar, Shweta
    Patre, Monika
    Strasak, Alexander
    Quartino, Angelica
    Jin, Jin Yan
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 175 - 185
  • [27] INDIRECT COMPARISON ANALYSIS TO EVALUATE THE CLINICAL EFFECTIVENESS OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS OTHER TREATMENTS FOR HER2-POSITIVE METASTATIC BREAST CANCER (MBC)
    Garcia, Benito E.
    Hersberger, V
    Takyar, S.
    Moser, A.
    VALUE IN HEALTH, 2013, 16 (07) : A395 - A395
  • [28] PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).
    Gebhart, Geraldine
    Lamberts, Laetitia E.
    Garcia, Camilo
    Ameye, Lieveke
    Stroobants, Sigrid
    Huizing, Manon
    Aftimos, Philippe G.
    Tol, Jolien
    Oyen, Wim J. G.
    Wimana, Zena
    van Dongen, G. A. M. S.
    Hoekstra, Otto S.
    Schroder, Carolien P.
    Gaye, Julie
    Menke, Catharina Wilhelmina
    Guiot, Thomas
    Brouwers, Adrienne H.
    Awada, Ahmad
    de Vries, Elisabeth G. E.
    Flamen, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
    Molinelli, Chiara
    Parisi, Francesca
    Razeti, Maria Grazia
    Arecco, Luca
    Cosso, Maurizio
    Fregatti, Piero
    Del Mastro, Lucia
    Poggio, Francesca
    Lambertini, Matteo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 241 - 250
  • [30] Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab
    Conte, B.
    Fabi, A.
    Poggio, F.
    Blondeaux, E.
    Dellepiane, C.
    D'Alonzo, A.
    Staiano, A.
    Buono, G.
    Arpino, G.
    Magri, V.
    Naso, G.
    Presti, D.
    Mura, S.
    Fontana, A.
    Cognetti, F.
    Molinelli, C.
    Pastorino, S.
    Bighin, C.
    Lambertini, M.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2018, 29
12345